GPC3 and neoplasm: As shown in Fig. 1a, in an IFN-γ ELISPOT assay, the HLA-A*02:01-restricted GPC3144–152 peptide-specific CTLs produced IFN-γ in the presence of GPC3-expressing tumor cells, HepG2 and SK-Hep-1/GPC3, without peptide pulse.